Clinical trials: Atopic Hypersensitivity
Atopic Dermatitis
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01859988
- Testing
- Dupilumab
- Where
- 84 sites in United States, Canada and 5 more
- Volunteers
- 380 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- Measure Up 1 (NCT03569293)
- Testing
- Upadacitinib
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 912 people
- Sponsor
- AbbVie
Atopic Dermatitis, Psoriasis
Evaluating Treatment Resistant Dermatitis TaroIIR
Psoriasis and atopic dermatitis are chronic inflammatory disease that account for a significant amount of patients in most dermatological practices.
- Trial name
- NCT03050294
- Testing
- Phone calls, Desoximetasone 0.25% spray
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Dermatitis, Atopic
Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Mepolizumab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that acts on Interleukin-5 (IL-5), which is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils…
- Trial name
- NCT03055195
- Testing
- Mepolizumab 100 mg
- Where
- 20 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
This is a first-in-human, randomized, double-blind, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, tolerability, and PK of ATI-1777 solution following twice-daily applications to target areas of…
- Trial name
- NCT04598269
- Testing
- ATI-1777, Vehicle
- Where
- 14 sites in United States
- Volunteers
- 50 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
- Trial name
- BREEZE-AD-PEDS (NCT03952559)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 78 sites in Argentina, Australia and 15 more
- Volunteers
- 516 people
- Sponsor
- Eli Lilly and Company
Moderate-to-Severe Atopic Dermatitis
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
- Trial name
- NCT03989349
- Testing
- Nemolizumab
- Where
- 138 sites in United States, Belgium and 9 more
- Volunteers
- 787 people
- Sponsor
- Galderma R&D
Hypersensitivity, Immediate Hypersensitivity
Oral Immunotherapy for Childhood Egg Allergy
The purpose of this study is to determine if oral immunotherapy (OIT) will desensitize a child with an allergy to egg and eventually lead to the development of tolerance to egg.
- Conditions
- Hypersensitivity, Immediate Hypersensitivity, Food Hypersensitivity
- Trial name
- NCT00461097
- Testing
- Egg oral immunotherapy, Control Group
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy, Dermatitis, Atopic
A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to evaluate the safety and tolerability of LY3844583 in healthy participants and participants with atopic dermatitis (AtD).
- Trial name
- NCT05486208
- Testing
- LY3844583
- Where
- 3 sites in United States, Japan
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these…
- Trial name
- LEADS (NCT05436535)
- Testing
- Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide
- Where
- 10 sites in United States
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.
- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, AD
- Trial name
- NCT05984784
- Testing
- IMG-007
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Inmagene LLC
Asthma, Allergic Sensitization
Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study
The purpose of this study is to determine whether early childhood exposure to common allergens (substances that can trigger allergies and asthma) can prevent the development of asthma in children at high risk for developing the…
- Trial name
- GPAC (NCT00346398)
- Testing
- Oral mucosal immunoprophylaxis (OMIP)
- Where
- 3 sites in United States, Australia
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
Study of 0416 Ointment in the Treatment of Atopic Dermatitis
The aim of this trial is to assess the efficacy of 0416 Ointment in the Treatment of Atopic Dermatitis. Treatment medication will be administered as follows: Apply a thin layer of ointment to affected skin areas twice daily and…
- Trial name
- NCT01053247
- Testing
- 0416, Vehicle of 0416 test product, tacrolimus ointment 0.1%
- Where
- United States
- Volunteers
- 793 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Atopic Dermatitis
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Level Up (NCT05601882)
- Testing
- Dupilumab, Upadacitinib
- Where
- 257 sites in United States, Australia and 27 more
- Volunteers
- 920 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children with Atopic Dermatitis. This is a randomized, double-blind, Vehicle Controlled study.
- Trial name
- NCT04921969
- Testing
- Ruxolitinib, Vehicle Cream
- Where
- 67 sites in United States, Canada
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
The purpose of this study is to assess the ease of use of the lebrikizumab pen. Participants will use a practice pad to simulate administration of a dose.
- Trial name
- NCT06444165
- Testing
- Lebrikizumab Pen
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis
Open-Label Study designed to evaluate the HPA axis suppression potential of Clobetasol Topical Oil and pharmacokinetic safety / systemic exposure to clobetasol when Clobetasol Topical Oil is applied to pediatric subjects with…
- Trial name
- NCT03847389
- Testing
- Clobetasol propionate 0.05% Topical Oil
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Hill Dermaceuticals, Inc.
Atopic Asthma
The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics
This study is designed to determine if treatment with abatacept is effective in decreasing allergic airway inflammation in mild, atopic asthmatics. Subjects will be recruited from the greater St Louis Metropolitan area.
- Trial name
- CIA (NCT00784459)
- Testing
- abatacept
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Atopic Dermatitis
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to <18 years weighing ≥40 kilograms) with moderate-to-severe atopic…
- Trial name
- ADore (NCT04250350)
- Testing
- Lebrikizumab
- Where
- 70 sites in United States, Australia and 2 more
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7
Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating severe AD in subjects who are not adequately controlled with or have…
- Trial name
- ECZTRA 7 (NCT03761537)
- Testing
- Tralokinumab
- Where
- 74 sites in Belgium, Czechia and 5 more
- Volunteers
- 277 people
- Sponsor
- LEO Pharma